Eckerdt Frank, Beauchamp Elspeth, Bell Jonathan, Iqbal Asneha, Su Bing, Fukunaga Rikiro, Lulla Rishi R, Goldman Stewart, Platanias Leonidas C
Robert H. Lurie Comprehensive Cancer Center and Division of Hematology- Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL,USA.
Robert H. Lurie Comprehensive Cancer Center and Division of Hematology- Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL,USA; Department of Medicine, Jesse Brown VA Medical Center, Chicago, IL, USA.
Oncotarget. 2014 Sep 30;5(18):8442-51. doi: 10.18632/oncotarget.2319.
The mTOR pathway controls mRNA translation of mitogenic proteins and is a central regulator of metabolism in malignant cells. Development of malignant cell resistance is a limiting factor to the effects of mTOR inhibitors, but the mechanisms accounting for such resistance are not well understood. We provide evidence that mTORC1 inhibition by rapamycin results in engagement of a negative feedback regulatory loop in malignant medulloblastoma cells, involving phosphorylation of the eukaryotic translation-initiation factor eIF4E. This eIF4E phosphorylation is Mnk2- mediated, but Mnk1-independent, and acts as a survival mechanism for medulloblastoma cells. Pharmacological targeting of Mnk1/2 or siRNA-mediated knockdown of Mnk2 sensitizes medulloblastoma cells to mTOR inhibition and promotes suppression of malignant cell proliferation and anchorage-independent growth. Altogether, these findings provide evidence for the existence of a Mnk2-controlled feedback loop in medulloblastoma cells that accounts for resistance to mTOR inhibitors, and raise the potential for combination treatments of mTOR and Mnk inhibitors for the treatment of medulloblastoma.
mTOR信号通路控制有丝分裂原蛋白的mRNA翻译,是恶性细胞代谢的核心调节因子。恶性细胞耐药性的产生是mTOR抑制剂疗效的限制因素,但导致这种耐药性的机制尚未完全明确。我们提供的证据表明,雷帕霉素对mTORC1的抑制作用会导致恶性髓母细胞瘤细胞中负反馈调节环的激活,这涉及真核翻译起始因子eIF4E的磷酸化。这种eIF4E磷酸化是由Mnk2介导的,但不依赖于Mnk1,并作为髓母细胞瘤细胞的一种存活机制。对Mnk1/2进行药物靶向或通过siRNA介导敲低Mnk2可使髓母细胞瘤细胞对mTOR抑制敏感,并促进对恶性细胞增殖和非锚定依赖性生长的抑制。总之,这些发现为髓母细胞瘤细胞中存在由Mnk2控制的反馈环提供了证据,该反馈环导致对mTOR抑制剂的耐药性,并提高了联合使用mTOR和Mnk抑制剂治疗髓母细胞瘤的可能性。